Apple, Facebook Among 5 Top Rated Big Cap Stocks
at Investor's Business Daily - Tue Aug 12, 7:35PM CDT
Stability is a critical determination in picking stock-watch candidates when the market is in correction. Today's Screen Of The Day is Big Cap Leaders, companies with top-notch fundamentals and a market capitalization of at least $15 billion. The...
Final Glance: Biotechnology companies
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.
Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 3:20PM CDT
Shares of Tekmira (TKMR) rose for the second successive day following the FDA announcement on TKM-Ebola.
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.
Midday Glance: Biotechnology companies
AP - Tue Aug 12, 12:47PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 12, 11:14AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:30AM CDT
Spectrum Pharmaceuticals (SPPI) reported second-quarter 2014 earnings of 16 cents per share, compared to the year-ago loss of 15 cents.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
Intercept Pharma Soars On Liver-Disease Drug Data
at Investor's Business Daily - Tue Aug 12, 9:48AM CDT
Biotech Intercept Pharmaceuticals (ICPT) was riding high on an upgrade and multiple price-target increases after it issued new data late Monday on its fatty-liver-disease drug candidate. Intercept Pharma stock vaulted 31% in early trading on the...
Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:38AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) reported second-quarter 2014 earnings per share of 6 cents compared to the year-ago loss of 57 cents.
Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 8:58AM CDT
Anacor Pharmaceuticals Inc (ANAC) reported second-quarter 2014 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 63 cents.
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 8:39AM CDT
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose roughly 7% on the day.
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:51AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as its shares rose over 10% on the day.
Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:29AM CDT
Gilead Sciences possess a Zacks Rank #1 (Strong Buy)and has witnessed a double digit EPS growth last year
'Mad Money' Lightning Round: I'm Not Crazy About El Pollo Loco
at The Street - Tue Aug 12, 5:00AM CDT
Cramer likes Arista Networks and thinks Energy Transfer Partners is a buy.
What is Your Stock's Earnings Yield? - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Aug 12, 2:17AM CDT
What is Your Stock's Earnings Yield? - Screen of the Week
Jim Cramer's 'Mad Money' Recap: Controlling Your Destiny
at The Street - Mon Aug 11, 7:03PM CDT
When you can't spur growth internally, you can make an acquisition, Cramer says.
After A Breakout, A Flat Base Can Yield New Entry
at Investor's Business Daily - Mon Aug 11, 5:18PM CDT
Growth stocks show strength in a down market in many different ways. They can show tight weekly closes after a breakout, refusing to give up much ground. Or, when they do pull back, they show supporting action at their 10-week moving average. Another...